Primary Progressive Multiple Sclerosis - Pipeline Insight, 2024

This “Primary Progressive Multiple Sclerosis- Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Primary Progressive Multiple Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Primary Progressive Multiple Sclerosis Understanding

Primary Progressive Multiple Sclerosis: Overview

Primary-progressive multiple sclerosis (PPMS) is a form of the disease that is characterized from the beginning of the disease as a progressively worsening condition. PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions. PPMS can be further characterized as either active (with an occasional relapse and/or evidence of new MRI activity over a specified period of time) or not active, as well as with progression (evidence of disability accrual over time, with or without relapse or new MRI activity) or without progression. This is in contrast to relapsing-remitting multiple sclerosis (RRMS) and secondary-progressive multiple sclerosis (SPMS), which are characterized by episodes of symptoms, brought on by inflammation, followed by periods of limited or no symptoms. The symptoms of primary-progressive multiple sclerosis are similar to those of secondary-progressive multiple sclerosis. The main symptom of both forms of the condition is a gradual worsening of disability. This may be experienced through increased:Fatigue,numbness or tingling,vision problems, such as double vision, spasticity or stiffness of the muscles, difficulty controlling the bladder or bowels, problems with cognition, such as learning and memory or information processing, difficulty with walking and coordination, trouble walking and muscle weakness. Ten percent of all multiple sclerosis patients are diagnosed with PPMS. The cause of PPMS is unknown. Patients with PPMS tend to be diagnosed in their mid-to-late 30s. The condition affects men and women equally. The only definitive way to diagnose PPMS apart from other forms of multiple sclerosis is by observation. In order to confirm a diagnosis of PPMS, the patient must: Have a year of consistent progression of the condition, including worsening neurologic function. Meet two of the following criteria: A type of lesion in the brain that is recognized by experts in as being typical of multiple sclerosis, two or more lesions of a similar type in the spinal cord. Evidence in the spinal fluid of oligoclonal bands or an elevated IgG index, both of which are indicative of immune system activity in the central nervous system. There is no cure for PPM, but it is not considered fatal. Although the FDA has approved medications for relapsing-remitting forms of the disease, there are currently no approved medications for PPMS. Treatment of PPMS is focused on managing the symptoms and increasing daily functioning. Symptoms of PPMS can affect a patient's daily life, so physical and occupational therapy may be used to manage symptoms and help patients adjust to living and working situations. Physical and occupational therapy may be helpful. For example, therapists may teach exercise strategies and how to manage new symptoms that develop.

Primary Progressive Multiple Sclerosis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Progressive Multiple Sclerosis pipeline landscape is provided which includes the disease overview and Primary Progressive Multiple Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Primary Progressive Multiple Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Progressive Multiple Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Primary Progressive Multiple Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Primary Progressive Multiple Sclerosis.

Primary Progressive Multiple Sclerosis Emerging Drugs Chapters

This segment of the Primary Progressive Multiple Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary Progressive Multiple Sclerosis Emerging Drugs

Tolebrutinib: SanofiTolebrutinib is an investigational brain-penetrant Bruton’s tyrosine kinase inhibitor that achieves CSF concentrations needed for targeting B lymphocytes and microglial cells. Tolebrutinib is being evaluated in Phase 3 clinical trials for the treatment of relapsing forms of MS (RMS), non-relapsing secondary progressive MS (nrSPMS), and primary progressive MS (PPMS), and its safety and efficacy have not been evaluated by any regulatory authority worldwide.

ATA 188: Atara BiotherapeuticsATA188, Atara’s investigational off-the-shelf T-cell candidate, has the potential to target EBV-infected B cells and plasma cells in the central nervous system that may catalyze autoimmune responses and MS pathophysiology. Atara is currently enrolling EMBOLD, a Phase 2 clinical study of ATA188 in the treatment of patients with progressive forms of MS, across clinical sites in North America and Australia.

Masitinib: AB ScienceMasitinib is designed for progressive forms of multiple sclerosis, targeting the innate immune system, specifically mast cells and microglia. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Primary Progressive Multiple Sclerosis.

Primary Progressive Multiple Sclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Primary Progressive Multiple Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Primary Progressive Multiple Sclerosis

There are approx. 10+ key companies which are developing the therapies for Primary Progressive Multiple Sclerosis. The companies which have their Primary Progressive Multiple Sclerosis drug candidates in the most advanced stage, i.e. phase III include, Sanofi.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Primary Progressive Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary Progressive Multiple Sclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Progressive Multiple Sclerosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Progressive Multiple Sclerosis drugs.

Primary Progressive Multiple Sclerosis Report Insights

• Primary Progressive Multiple Sclerosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Primary Progressive Multiple Sclerosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Primary Progressive Multiple Sclerosis drugs?
• How many Primary Progressive Multiple Sclerosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Progressive Multiple Sclerosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Primary Progressive Multiple Sclerosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Primary Progressive Multiple Sclerosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Atara Biotherapeutics
• AB Science
• Sanofi
• MediciNova

Key Products

• ATA 188
• Tolebrutinib
• Masitinib
• Ibudilast

This product will be delivered within 2 business days.